

1 Differential antibody production by symptomatology in SARS-CoV-2 2 convalescent individuals

3
4 Sharada Saraf¹, Xianming Zhu², Ruchee Shrestha², Tania S. Bonny^{2§}, Owen R. Baker³, Evan J.
5 Beck¹, Reinaldo E. Fernandez³, Yolanda Eby², Olivia Akinde², Jessica E. Ruff², Patrizio
6 Caturegli², Andrew D. Redd^{1,3}, Evan M. Bloch², Thomas C. Quinn^{1,2,3}, Aaron AR Tobian^{2,3,4},
7 Oliver Laeyendecker^{1,3*}

8
9 ¹ Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National
10 Institutes of Health, Bethesda, Maryland, USA.

11 ² Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

12 ³ Department of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine,
13 Baltimore, Maryland, USA.

14 ⁴ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,
15 Maryland, USA.

16 § Current Affiliation: U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

17
18 *Corresponding Author:

19 Oliver Laeyendecker
20 855 North Wolfe Street
21 Rangos Building, Room 538A
22 Baltimore, MD 21205
23 Email: olaeyen1@jhmi.edu

24 25 **Conflict of interest statement**

26 The authors have declared that no competing interests exist

27

28 **Abstract**

29 The association between COVID-19 symptoms and antibody responses against SARS-CoV-2 is
30 poorly characterized. We analyzed antibody levels in individuals with known SARS-CoV-2
31 infection to identify potential antibody-symptom associations. Convalescent plasma from 216
32 SARS-CoV-2 RNA+ individuals with symptomatology information were tested for the presence
33 of IgG to the spike S1 subunit (Euroimmun ELISA), IgG to receptor binding domain (RBD,
34 CoronaCHEK rapid test), and for IgG, IgA, and IgM to nucleocapsid (N, Bio-Rad ELISA).
35 Logistic regression was used to estimate the odds of having a COVID-19 symptom from the
36 antibody response, adjusting for sex and age. Cough strongly associated with antibodies against
37 S1 (adjusted odds ratio [aOR]= 5.33; 95% CI from 1.51 to 18.86) and RBD (aOR=4.36; CI 1.49,
38 12.78). In contrast, sore throat significantly associated with the absence of antibodies to S1 and
39 N (aOR=0.25; CI 0.08, 0.80 and aOR=0.31; 0.11, 0.91). Similarly, lack of symptoms associated
40 with the absence of antibodies to N and RBD (aOR=0.16; CI 0.03, 0.97 and aOR=0.16; CI 0.03,
41 1.01). Cough appeared to be correlated with a seropositive result, suggesting that SARS-CoV-2
42 infected individuals exhibiting lower respiratory symptoms generate a robust antibody response.
43 Conversely, those without symptoms or limited to a sore throat while infected with SARS-CoV-2
44 were likely to lack a detectable antibody response. These findings strongly support the notion
45 that severity of infection correlates with robust antibody response.

46

47

48

49

50

51 **Introduction**

52 The ongoing COVID-19 pandemic has challenged health care systems globally and
53 necessitated rapid deployment of treatments and vaccines. SARS-CoV-2 infection, the causative
54 agent of COVID-19, elicits a broad range of symptoms: fever, cough, shortness of breath, and
55 myalgia are the most reported symptoms among critically ill patients.¹ Antibody levels serve as a
56 potential correlate of protection against COVID-19; individuals who test positive for anti-spike
57 and anti-nucleocapsid IgG antibodies have demonstrated a substantially reduced risk of SARS-
58 CoV-2 reinfection.² Moreover, high vaccine-induced antibody responses are associated with
59 lower risk of symptomatic COVID-19.³

60 Previous studies have observed higher prevalence of seroconversion among severely ill
61 individuals versus those with asymptomatic or mild disease.⁴ Additionally, studies have shown
62 that males, older individuals, and those previously hospitalized with symptoms generate strong
63 antibody responses.⁵ SARS-CoV-2 antibody levels have been demonstrated to positively
64 correlate with the severity of COVID-19; however, the immune responses of individuals
65 experiencing milder disease remain poorly characterized.⁶⁻⁸ Investigating possible correlations
66 with symptomatology can add more nuance to characterizing population level immunity or
67 seroprevalence in a certain population, thus informing future public health interventions.^{7,9}
68 Furthermore, these data may help inform whether previously infected individuals have a higher
69 chance of re-infection depending on their symptom presentation during their disease course,
70 which can better characterize the urgency of vaccination in these individuals.^{10,11}

71 We investigated whether certain symptoms are predictive of a stronger antibody response by
72 analyzing the antibody levels of individuals with known SARS-CoV-2 infection for associations
73 between antibody response and reported symptoms. Samples from individuals who recovered

74 from SARS-CoV-2 infection were tested for the presence of IgG antibodies to spike (S1), IgG
75 antibodies to the receptor binding domain (RBD), and total antibodies to nucleocapsid (N).

76

77 **Materials and Methods**

78 **Study Participants**

79 This study used stored samples and data from studies that were approved by The Johns
80 Hopkins University School of Medicine Institutional Review Board. All study participants
81 provided written informed consent and were de-identified prior to laboratory testing.

82 To assess the antibody levels of SARS-CoV-2 infected individuals, samples from 216
83 participants from the Baltimore/Washington DC area who were screened to donate COVID-19
84 convalescent plasma (CCP) and had accompanying symptom data from April 2020-January 2021
85 were evaluated.^{5,12,13} All were at least 18 years old and met the eligibility criteria for blood
86 donation.

87

88 **Ascertainment of the symptomatology**

89 As a part of a phone screening, participants were asked by a study team member if they were
90 hospitalized and/or experienced any symptoms during their illness and, if so, to list their
91 symptoms. Participant answers were then recorded by the screener according to 17 standard
92 categories: no symptoms, fever, cough, chills, shortness of breath, diarrhea, fatigue, anosmia,
93 dysgeusia, sore throat, headache, muscle ache, runny nose, stuffy nose, nausea, vomiting, or
94 other.

95

96 **Laboratory Methods**

97 Plasma was separated from whole blood within 12 hours of collection and stored at -80°C
98 until further testing. Samples were analyzed using three commercially available serologic assays:
99 Euroimmun Anti-SARS-CoV-2 ELISA (Mountain Lakes, NJ), the CoronaCHEK™ COVID-19
100 IgG/IgM Rapid Test Cassette (Hangzhou Biotest Biotech Co Ltd), and the Bio-Rad Platelia
101 SARS-CoV-2 Total Antibody ELISA (Marnes-la-Coquette, France). The Euroimmun ELISA
102 measures IgG responses to the SARS-CoV-2 S1 protein, whereas the CoronaCHEK rapid test
103 measures IgG responses to the SARS-CoV-2 RBD.^{14,15} The Bio-Rad ELISA measures total
104 antibody response to the SARS-CoV-2 N.¹⁶

105 Thirty-five cytokine and chemokine analytes in plasma were assessed using a multi-array
106 electrochemiluminescence detection technology (MesoScale Discovery, Gaithersburg, MD) as
107 previously described.¹⁷ Analytes with $\geq 80\%$ overall detectability were evaluated for cytokine
108 level differences between symptom groups and included Eotaxin, Eotaxin-3, IFN- γ , IL-
109 12/IL23p40, IL-15, IL-16, IL-17A, IL-18, IL-1RA, IL-6, IL-7, IL-8, IP-10, MCP-1, MCP-4,
110 MDC, MIP-1B, TARC, TNF- α , and VEGF-A. Analytes with $< 80\%$ overall detectability were
111 evaluated for percent detectability differences between symptom groups and included IL-12p70,
112 IL-13, IL-1B, IL-2, IL-4, G-CSF, IFN- $\alpha 2\alpha$, IL-21, IL-33, IL-8(HA), MIP-1a, GM-CSF, IL-1a,
113 IL-5, and TNF-B. All assays were performed according to the manufacturer's protocols.

114

115 **Statistical Analysis**

116 Binomial logistic regressions were performed to calculate odds ratios [OR] for associations
117 between serological results and reported symptoms. Adjusted odds ratios [aOR] were calculated
118 for all symptoms. Based on previous studies linking sex and age to antibody reactivity, these

119 were considered to be confounding variables and therefore included in adjusted models.⁵

120 Adjusted odds ratios with a $p < 0.05$ were considered significant. All analysis were performed in

121 STATA v.14.2 (College Station, TX).

122

123 Results

124 Participants were a median age of 49 years (IQR 37-58) at the time of sample collection. This

125 subject pool was 81.9% White, 9.7% Black, 4.2% Asian, and 4.2% mixed/other/unknown (**Table**

126 **1**). A median of 49 days (IQR 40-64) had elapsed since participants had a confirmed SARS-

127 CoV-2 diagnosis via detectable RNA.

128

129 **Table 1. Demographic data of convalescent plasma donors**

	All	Female	Male
Number of individuals	216	137	79
Median age (IQR)	49 (37-58)	49 (37-57)	49 (38-61)
Age categories			
19-44	85	54	31
45-64	106	69	37
65+	25	14	11
Race/ethnicity			
White	177	111	66
Black	21	15	6
Asian	9	7	2
Other	9	4	5
Median days post PCR+ blood collection (IQR)	49 (40-64)	54 (42-75)	43 (38-58)

130 Abbreviations: IQR, inter quartile range

131

132 Of the 17 different categories, the most frequently reported were fatigue (53%), fever (50%),

133 and cough (50%) (**Fig 1**). Headache (44%), muscle ache (43%), loss of smell (38%), altered taste

134 (33%), short breath (26%), stuffy nose (25%), and sore throat (20%) were also commonly

135 reported. Chills (16%), diarrhea (15%), nausea (9%), runny nose (8%), no symptoms (5%), and
136 vomiting (3%) were the least recorded categories. Hospitalization occurred in 7% of all
137 participants. Individuals reporting fatigue also commonly reported headache (29%), fever (26%),
138 cough (26%), and muscle ache (26%).

139

140 **Figure 1. Frequency and Correlation of COVID-19 Symptoms**

141 Percentage of individuals with the symptoms or pairs of symptoms are presented. Symptom or
142 symptom pairs prevalent in >10% of individuals are colored.

143

144 For each of the three serologic assays, >83% of all samples had a positive result. All
145 individuals who were hospitalized had reactive plasma to the Euroimmun ELISA,
146 CoronaCHECK (IgG) rapid test, and Bio-Rad ELISA. For individuals reporting shortness of
147 breath reactivity on Euroimmun, CoronaCHECK IgG, and Bio-Rad assays were positive on
148 93%, 91%, and 86% respectively. Other symptoms had similar consistency in reactivity, with
149 fever and cough specifically demonstrating a similar range of percent reactivity (88-94%) across
150 the three assays. Similarly, lack of reactivity to these two assays appeared to be consistent, with
151 the exception of vomiting. Lack of symptoms (40-60%) and sore throat (73-75%) demonstrated
152 relative stability across all three assays.

153

154 **Figure 2. Reactivity of Antibody Assays by Presenting Symptoms**

155

156 Percent reactivity was calculated by dividing the number of individuals with positive antibody
157 results reporting the indicated symptom by the total number of individuals reporting the
158 indicated symptom.

159

160 Signal to cut-off ratios (S/C) were generated for the Euroimmun and BioRad ELISAs. These
161 results were stratified by five symptom categories: cough, sore throat, no symptoms, and other
162 symptoms. For the Bio-Rad assay, individuals reporting cough or other symptoms had the
163 highest mean S/C ratio. Sore throat and no symptoms had the lowest mean S/C ratio. Similarly,
164 the highest S/C ratios on the Euroimmun assay were generated by samples from individuals
165 reporting cough, other symptoms, sore throat, and no symptoms.

166

167 **Fig 3. Antibody Reactivity to Nucleocapsid Protein as measured by Bio-Rad ELISA and S1**
168 **Protein as measured by Euroimmun ELISA Stratified by Symptom Category.**

169

170 Solid horizontal lines represent the mean S/C ratio for the indicated symptom group. Dashed
171 horizontal line represents the positive result threshold for the indicated assay.

172

173 Individuals reporting cough had the strongest association with a positive antibody response to
174 S1 (aOR=5.33; 95% CI 1.51, 18.86) and RBD (aOR=4.36; CI 1.49, 12.78) though not to N
175 (**Table 2**). In contrast, sore throat was significantly associated with a lack of detectable antibody
176 response to S1 and N (aOR=0.25; CI 0.08, 0.80 and aOR=0.31; 0.11, 0.91), respectively.
177 Reporting a lack of symptoms was associated with a lack of antibody response to N (aOR=0.16;
178 CI 0.03, 0.97) and to RBD, though this association did not reach a statistical significance of
179 <0.05 (aOR=0.16; CI 0.03, 1.01). Individuals reporting diarrhea demonstrated decreased
180 reactivity to N (aOR=0.17; CI 0.05, 0.62), whereas stuffy nose displayed increased reactivity to
181 N (aOR=5.07; CI 0.93, 27.71). Notably, aORs and confidence intervals did not significantly
182 attenuate after adjustment across assays for cough, sore throat, or no symptoms.

183

Table 2. Association between symptoms and antibody reactivity to S1, RBD and N proteins of SARS-CoV-2 among infected individuals

Variable ¹	Euroimmun IgG S1 Positive Result ²		CoronaCHEK RBD Positive Result ²		BioRad Total Ab N Positive Result ²	
	Crude Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI) ³	Crude Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI) ³	Crude Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI) ³
Cough (n=110)	5.82 (2.12, 16.0) ‡	5.33 (1.51, 18.86) ‡	5.82 (2.19, 12.7) ‡	4.36 (1.49, 12.78) ‡	1.97 (0.89, 4.36)	1.51 (0.55, 4.13)
Altered taste (n=72)	1.59 (0.64, 3.93)	0.68 (0.14, 3.26)	3.52 (1.31, 9.53) †	3.48 (0.82, 14.82)	1.44 (0.61, 3.42)	0.75 (0.18, 3.17)
Sore Throat (n=45)	0.28 (0.12, 0.66) ‡	0.25 (0.08, 0.80) †	0.43 (0.19, 0.94) †	0.48 (0.16, 1.38)	0.39 (0.17, 0.87) †	0.31 (0.11, 0.91) †
Muscle ache (n=92)	1.67 (0.72, 3.88)	1.87 (0.63, 5.49)	2.45 (1.09, 5.51) †	2.25 (0.83, 6.09)	1.58 (0.70, 3.55)	2.23 (0.79, 6.26)
Diarrhea (n=33)	0.81 (0.28, 2.29)	0.33 (0.08, 1.39)	1.10 (0.39, 3.07)	0.77 (0.19, 2.67)	0.53 (0.21, 1.37)	0.17 (0.05, 0.62) ‡
Stuffy nose (n=39)	0.78 (0.29, 2.08)	1.55 (0.41, 5.84)	0.86 (0.35, 2.14)	0.83 (0.25, 2.77)	3.48 (0.79, 15.26)	5.07 (0.93, 27.71) †
No symptoms (n=10)	0.20 (0.05, 0.75) †	0.24 (0.04, 1.49)	0.11 (0.03, 0.41) ‡	0.16 (0.03, 1.01)	0.22 (0.06, 0.82) †	0.16 (0.03, 0.97) †

¹Symptoms with no significant association with antibody reactivity found: fatigue (n=115), fever (n=111), headache (n=95), anosmia (n=83), shortness of breath (n=57), chills (n=35), nausea (n=20), runny nose (n=18), vomiting (n=7), other (n=23).

²Abbreviation: S1, spike protein subunit 1; RBD, receptor binding domain; N, nucleocapsid; CI, confidence interval; n, number.

³Variables in the adjusted model included sex, age, and all symptom predictor variables.

† p< 0.05, ‡ p< 0.01.

184

185 To further investigate the seronegativity of individuals reporting sore throat, individuals were
186 grouped into three categories: whether they reported no symptoms, reported symptoms other
187 than sore throat, or reported sore throat. Individuals who reported a sore throat and cough as co-
188 symptoms were placed in the second category. Among the analytes with $\geq 80\%$ overall
189 detectability, the median cytokine levels were not significantly higher among convalescent
190 individuals who were symptomatic, asymptomatic, or reporting sore throat (**Fig 4**). Among the
191 analytes with $< 80\%$ overall detectability, the percent detectability analytes in individuals
192 reporting sore throat (no cough) versus other symptoms were not significantly different (**Fig 5**).

193

194 **Figure 4. Cytokine levels by symptom group**

195

196 **Figure 5. Detectability of cytokine markers by response panel and symptom group**

197

198 **Discussion**

199 This study demonstrates associations between symptom presentation and antibody assay
200 reactivity. Assay reactivity appears to be consistent across symptoms, suggesting that antibodies
201 produced by convalescent individuals share a similar responsiveness to different parts of the
202 virus regardless of symptom presentation. In addition to hospitalization and male sex, reporting
203 cough appeared to be predictive of a seropositive result, suggesting that these individuals may be
204 more likely to generate a robust antibody response. Conversely, sore throat and no symptoms
205 were associated with a seronegative result.

206 Previous studies have demonstrated higher antibody titers in individuals exhibiting more
207 symptomatic disease.^{4,18} Our results are complementary to these findings, given that
208 asymptomatic convalescent individuals were significantly associated with a seronegative result.
209 Strikingly, our study demonstrates the single symptom of sore throat being associated with a
210 seronegative result. This finding has not been demonstrated in prior studies investigating
211 COVID-19 symptoms and antibody reactivity. However, the lower and upper respiratory tract
212 has shown to differ in their mechanisms of immunity, with sore throat being a presenting
213 symptom of an upper respiratory tract infection.¹⁹⁻²¹

214 Studies regarding influenza have demonstrated robust IgG responses to be more indicative of
215 a lower respiratory tract infection.^{22,23} Moreover, others have suggested that the progress of
216 COVID-19 disease, when confined to the upper respiratory tract, typically appears to resolve
217 with minimal to no symptoms.²⁴ This literature may serve as a potential explanation as to why
218 convalescent individuals in this study reporting no symptoms and sore throat generate fewer IgG
219 antibodies. Alternatively, a strong innate immune response may serve to effectively combat the

220 virus in these convalescent individuals, thus not necessitating a robust antibody response;
221 however, our cytokine and chemokine data do not support this rationalization. Given that a
222 median of 30 days had passed since symptom resolution in this subject pool at the time of blood
223 collection, it is possible that cytokine and chemokine levels may have declined to their basal
224 levels.²⁵

225 Our study had several limitations. First, capture of clinical symptoms was based on self-
226 reporting rather than review of the patients' medical records. Individuals reporting a certain
227 symptom may have experienced a more severe presentation than others reporting the same
228 symptom, which was not captured by this dataset and may have influenced antibody production.
229 Second, samples were obtained a median of 49 days after participants had PCR positive results
230 and 30 days post symptom resolution. Antibody levels may have declined at the time of sample
231 collection; furthermore, samples were collected at only one timepoint and inferences about
232 persistently high titers of antibodies based on symptom cannot be made.

233 In this cohort of known SARS-CoV-2 infected individuals, we found a strong association
234 between cough and antibody response. Conversely, a sore throat was strongly associated with a
235 lack of antibody response to SARS-CoV-2 infection. Future studies could test for IgA levels in
236 nasal or throat samples to evaluate whether a robust mucosal IgA response is associated with
237 certain clinical presentations of COVID-19. Immune factors other than antibodies and our panel
238 of human cytokines may also be evaluated to better characterize the immune responses generated
239 by individuals exhibiting particular symptomatology.

240

241 **Acknowledgments** The authors would like to thank the participants who donated their
242 plasma and the study trial staff, without whom this investigation could not be conducted.

243 **References**

- 244 1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-
245 CoV-2 pneumonia in wuhan, china: A single-centered, retrospective, observational study. *The*
246 *Lancet Respiratory Medicine*. 2020;8(5):475-481.
- 247 2. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody status and incidence of SARS-CoV-2
248 infection in health care workers. *New England Journal of Medicine*. 2021;384(6):533-540.
- 249 3. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
250 asymptomatic SARS-CoV-2 infection. *Nature Medicine* 2021 27:11. 2021;27(11):2032-2040.
- 251 4. Bartsch YC, Fischinger S, Siddiqui SM, et al. Discrete SARS-CoV-2 antibody titers track with
252 functional humoral stability. *Nature Communications* 2021 12:1. 2021;12(1):1-8.
- 253 5. Klein SL, Pekosz A, Park H, et al. Sex, age, and hospitalization drive antibody responses in a
254 COVID-19 convalescent plasma donor population. *J Clin Invest*. 2020;130(11):6141-6150.
255 Accessed Jan 7, 2022. doi: 10.1172/JCI142004.
- 256 6. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic
257 SARS-CoV-2 infections. *Nature Medicine* 2020 26:8. 2020;26(8):1200-1204.
- 258 7. Grossberg AN, Koza LA, Ledreux A, et al. A multiplex chemiluminescent immunoassay for
259 serological profiling of COVID-19-positive symptomatic and asymptomatic patients. *Nature*
260 *Communications* 2021 12:1. 2021;12(1):1-11.

- 261 8. Caturegli G, Materi J, Howard BM, Caturegli P. Clinical validity of serum antibodies to
262 SARS-CoV-2. *Ann Intern Med.* 2020;173(8):614-622.
263 <https://www.acpjournals.org/doi/10.7326/M20-2889>. Accessed Jan 20, 2022. doi: 10.7326/M20-
264 2889.
- 265 9. Smith DR. Herd immunity. *Veterinary Clinics of North America: Food Animal Practice.*
266 2019;35(3):593-604.
- 267 10. Townsend JP, Hassler HB, Wang Z, et al. The durability of immunity against reinfection by
268 SARS-CoV-2: A comparative evolutionary study. *The Lancet Microbe.* 2021;2(12):e666-e675.
- 269 11. Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced risk of reinfection
270 with SARS-CoV-2 after COVID-19 vaccination — kentucky, May–June 2021. *MMWR.*
271 *Morbidity and Mortality Weekly Report.* 2021;70(32):1081-1083.
- 272 12. Patel EU, Bloch EM, Clarke W, et al. Comparative performance of five commercially
273 available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high
274 neutralizing titers. *Journal of Clinical Microbiology.* 2020.
275 <https://journals.asm.org/doi/abs/10.1128/JCM.02257-20>. Accessed Jan 11, 2022. doi:
276 10.1128/JCM.02257-20.
- 277 13. Benner SE, Patel EU, Laeyendecker O, et al. SARS-CoV-2 antibody avidity responses in
278 COVID-19 patients and convalescent plasma donors. *The Journal of Infectious Diseases.*
279 2020;222(12):1974-1984.

- 280 14. EUROIMMUN US. Anti-SARS-CoV-2 ELISA (IgG) instruction for use.
281 <https://www.fda.gov/media/137609/download>. Updated 2020.
- 282 15. Healgen. COVID-19 IgG/IgM rapid test cassette (whole blood/serum/plasma) instruction for
283 use. <https://www.fda.gov/media/138438/download>. Updated 2020.
- 284 16. Bio-Rad Laboratories. Platelia SARS-CoV-2 total ab. . Updated 2020.
- 285 17. Bonny TS, Patel EU, Zhu X, et al. Cytokine and chemokine levels in coronavirus disease
286 2019 convalescent plasma. *Open Forum Infectious Diseases*. 2021;8(2).
- 287 18. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with
288 COVID-19. *Nature Medicine* 2020 26:6. 2020;26(6):845-848.
- 289 19. Hodge LM, Simecka JW. Role of upper and lower respiratory tract immunity in resistance to
290 mycoplasma respiratory disease. *The Journal of Infectious Diseases*. 2002;186(2):290-294.
- 291 20. Subbarao K, Mahanty S. Respiratory virus infections: Understanding COVID-19. *Immunity*.
292 2020;52(6):905.
- 293 21. Thomas M, Bomar PA. Upper respiratory tract infection. *Medscape*. 2021:1-18.
- 294 22. Renegar KB, Small PA, Boykins LG, Wright PF. Role of IgA versus IgG in the control of
295 influenza viral infection in the murine respiratory tract. *The Journal of Immunology*.
296 2004;173(3):1978-1986.
- 297 23. Ito R, Ozaki YA, Yoshikawa T, et al. Roles of anti-hemagglutinin IgA and IgG antibodies in
298 different sites of the respiratory tract of vaccinated mice in preventing lethal influenza

299 pneumonia. *Vaccine*. 2003;21(19):2362-2371.

300 <https://www.sciencedirect.com/science/article/pii/S0264410X03000781>. Accessed Jan 12, 2022.

301 doi: 10.1016/S0264-410X(03)00078-1.

302 24. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. Mucosal immunity in COVID-19: A
303 neglected but critical aspect of SARS-CoV-2 infection. *Frontiers in Immunology*. 2020;11:3221.

304 25. Whiteside TL. Cytokines and cytokine measurements in a clinical laboratory. *Clin Diagn Lab*
305 *Immunol*. 1994;1(3):257-260. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC368245/>.

306 Accessed Jan 20, 2022.

307




Figure 1




Figure 2





Figure 3








Figure 4



Legend: ■ No symptoms ■ Sore throat (no cough) ■ Other symptoms

Figure 5